RxDoctor Payments DataLook up a doctor →

Alexandru Barboi, MD

Neurology · Indianapolis, INNPI 1295785723

Payments from drug & device makers

$1,855,718in general payments, 2019–2025

Across 773 payments — averaging $2400.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$957K
  • H. Lundbeck A S$538K
  • UCB SA$159K
  • Regeneron$113K
  • Catalyst Pharmaceuticals, Inc.$87K
  • UCB Biosciences Inc.$2K
  • plus $304 from 5 others

What the payments were for

  • Food & beverage$468100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,855,718 in reported general payments places this provider in the 95th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$51,058
Medicare patients
256
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$283,208
HizentraImmun Glob G(Igg)/Pro/Iga 0-5022$116,065
GammakedImmune Globul G/Gly/Iga Avg 4615$86,292
Droxidopa94$77,879
Gamunex-CImmune Globul G/Gly/Iga Avg 4636$59,154
CorlanorIvabradine Hcl42$38,345
Aimovig AutoinjectorErenumab-Aooe26$18,976
Mycophenolate Mofetil17$4,614
Midodrine Hcl96$4,516
Pyridostigmine Bromide28$3,273
Gabapentin72$1,357
Fludrocortisone Acetate49$1,342
Pregabalin38$1,191
Armodafinil24$1,117
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine26$1,015

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kedrion Biopharma, Inc.Gammaked$15$86,29215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 neurology providers in Indiana.

Other neurology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →